PROMIS NEUROSCIENCES
ProMIS Neurosciences is a development-stage biotech company that discovers and develops precision therapeutics and companion diagnostics for early detection and effective treatment of neurodegenerative diseases, in particular, Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). It was founded in 2004 and headquartered in Toronto, Canada.
PROMIS NEUROSCIENCES
Industry:
Biotechnology Health Diagnostics Medical Neuroscience Therapeutics
Founded:
2004-01-01
Address:
Toronto, Ontario, Canada
Country:
Canada
Website Url:
http://www.promisneurosciences.com
Total Employee:
1+
Status:
Active
Contact:
(416) 847-6898
Email Addresses:
[email protected]
Total Funding:
162.17 M USD
Technology used in webpage:
Euro Google Adsense Amazon Ireland Region
Similar Organizations
Arctic Therapeutics
Arctic Therapeutics (AT) uses bioinformatic approaches and AI to eliminate major risks associated with traditional drug development.
Dimension Therapeutics
Dimension Therapeutics is a gene therapy company developing novel treatments for rare diseases.
Eden Biologics
Eden Biologics is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners.
Prolocor
Prolocor is a biotechnology company that develops diagnostic tests for cardiovascular diseases.
Slingshot Biosciences
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Visterra
Visterra researches on and develops therapeutic and diagnostic products for the treatment of infectious diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Armistice Capital
Armistice Capital investment in Post-IPO Equity - ProMIS Neurosciences
Great Point Partners
Great Point Partners investment in Post-IPO Equity - ProMIS Neurosciences
Sphera Global Healthcare Fund
Sphera Global Healthcare Fund investment in Post-IPO Equity - ProMIS Neurosciences
Ally Bridge Group
Ally Bridge Group investment in Post-IPO Equity - ProMIS Neurosciences
Sphera Global Healthcare Fund
Sphera Global Healthcare Fund investment in Post-IPO Equity - ProMIS Neurosciences
Affinity Asset Advisors
Affinity Asset Advisors investment in Post-IPO Equity - ProMIS Neurosciences
Ally Bridge Group
Ally Bridge Group investment in Post-IPO Equity - ProMIS Neurosciences
Key Employee Changes
Official Site Inspections
http://www.promisneurosciences.com Semrush global rank: 6.31 M Semrush visits lastest month: 1.05 K
- Host name: ec2-174-129-30-187.compute-1.amazonaws.com
- IP address: 174.129.30.187
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "ProMIS Neurosciences"
About :: ProMIS Neurosciences, Inc. (PMN)
Harnessing The Power of Selective Targeting of Toxic Oligomers to Combat Neurodegenerative Diseases and other Misfolded Protein Diseases. ProMIS Neurosciences is a clinical-stage biotechnology company committed to the …See details»
Management Team :: ProMIS Neurosciences, Inc. (PMN)
All these experiences are backed by nearly twenty-years with Genzyme, leading the rare …See details»
ProMIS Neurosciences - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number (416) 847-6898 ProMIS …See details»
Investors :: ProMIS Neurosciences, Inc. (PMN)
Company Overview. ProMISâ„¢ Neurosciences, Inc. (Nasdaq: PMN), is a clinical-stage …See details»
ProMISâ„¢ Neurosciences, Inc. | LinkedIn
ProMIS Neurosciences' CEO, Neil Warma, recently sat down with CEOCFO Magazine to …See details»
ProMISâ„¢ Neurosciences, Inc. | LinkedIn
ProMISâ„¢ Neurosciences, Inc. Biotechnology Research Toronto, Ontario 1,847 followers Developing next-generation disease-modifying treatments for Alzheimer’s, ALS, and multiple system atrophy.See details»
ProMIS Neurosciences, Inc. (PMN) Company Profile & Overview
Oct 22, 2024 Ticker Symbol: PMN: Exchange: NASDAQ: Fiscal Year: January - December: …See details»
ProMIS Neurosciences, Inc. (PMN) - Yahoo Finance
Find the latest ProMIS Neurosciences, Inc. (PMN) stock quote, history, news and other vital …See details»
ProMIS Neurosciences, Inc. Announces Leadership Transition
Jan 3, 2024 Appoints Neil Warma, Industry Leader and ProMIS Board Member, as Interim …See details»
ProMIS Neurosciences Achieves Milestone in Development of …
Jan 22, 2024 Lead vaccine candidate selected for advancement against synucleinopathies …See details»
ProMIS Neurosciences, Inc. Announces Leadership Transition
Jan 3, 2024 Visit us at www.promisneurosciences.com. Please submit media inquiries to …See details»
ProMIS Neurosciences, Inc. (PMN) - Stock Analysis
5 days ago ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and …See details»
ProMIS Neurosciences Reports Positive Top-Line Data from
Jul 26, 2024 Please submit media inquiries to [email protected]. For Investor …See details»
ProMIS Neurosciences Reports New Milestones in Potential …
Apr 28, 2022 In an aggressive mouse model of ALS/FTD conducted at a contract research …See details»
ProMIS Neurosciences Announces FDA Clearance of …
May 8, 2023 TORONTO, Ontario and CAMBRIDGE, Massachusetts, May 08, 2023 (GLOBE …See details»
ProMIS Neurosciences Announces Fiscal Year 2021 Results
Mar 17, 2022 The increase in research and development expense for the year ended …See details»
ProMIS Neurosciences to Present in Upcoming Investor …
Apr 4, 2024 A live webcast of the presentations may be accessed by visiting the Events page …See details»
ProMIS Neurosciences Announces Third Quarter 2021 Results
TORONTO and CAMBRIDGE, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- ProMIS …See details»